The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

For Immediate Release

Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Emergent BioSolutions Inc. EBS, Vertex Pharmaceuticals Incorporated VRTX, Editas Medicine, Inc. EDIT, Cellectis S.A. CLLS and Thermo Fisher Scientific Inc. TMO.

Here are highlights from Monday’s Analyst Blog:

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

The biotech space has been booming in the past decade, with areas like gene editing stealing the show as they increase scope for treating life-threatening diseases. Gene editing or genome engineering is a process in which a DNA is inserted, modified or replaced in the genome of any living organism. In recent years, scientists have been using gene editing technology to help treat diseases

Read More

CRSwNP Highlights From the AAO-HNSF 2020 Virtual Meeting

The annual American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNSF) 2020 Meeting was held virtually this year and also included abstracts from the American Rhinologic Society Annual Meeting.

Stella Lee, MD, chief of the Division of Sino-Nasal Disorder and Allergy at the University of Pittsburgh Medical Center, reviews important studies and data presented at the meeting that could have important implications for patient care.

Dr Lee highlights developments in the use of protein biomarkers to help determine potential efficacy of systemic steroid therapy in postsurgical patients with CRSwNP. The study could aid in the prevention of overtreatment in certain patients.

Biologic therapies approved for use in asthma management continue to show efficacy in patients with CRSwNP. The results of the SYNAPSE study of mepolizumab, an anti-IL-5 biologic therapy, showed clear clinical benefit in patients with CRSwNP. The multi-institutional, phase 3 study met primary endpoints and showed that mepolizumab reduced the

Read More